Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

Mirakhorli,Mojgan; Rahman,Sabariah  Abdul; Abdullah,Syahrilnizam; Vakili,Masoud; Rozafzon,Reza; Khoshzaban,Ahad

doi:10.3892/mmr.2012.1226

Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

Authors:
- Mojgan Mirakhorli
- Sabariah Abdul Rahman
- Syahrilnizam Abdullah
- Masoud Vakili
- Reza Rozafzon
- Ahad Khoshzaban
View Affiliations

Affiliations: Department of Pathology, Faculty of Medicine and Health Sciences, University Putra Malaysia, Serdang, Selangor 43400, Malaysia, Medical Genetics Laboratory, Faculty of Medicine and Health Sciences, University Putra Malaysia, UPM Serdang, Selangor 43400, Malaysia, Department of Oncology, Hazrate Rasoul Akram Hospital, Tehran University of Medical Science, Tehran, Iran, Stem Cell Preparation Unit, Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Science, Tehran, Iran
Published online on: December 7, 2012 https://doi.org/10.3892/mmr.2012.1226
Pages: 613-617

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance protein 2 (MRP2), encoded by the ATP-binding cassette C2 (ABCC2) gene, is an efflux pump located on the apical membrane of many polarized cells, which transports conjugate compounds by an ATP-dependent mechanism. The correlation of G1249A ABCC2 polymorphism with the development of colorectal cancer (CRC) and poor prognosis was evaluated in patients who were treated with fluorouracil/leucovorin (FL) plus oxaliplatin (FOLFOX-4). A total of 50 paraffin‑embedded tissue samples collected from CRC patients were analyzed to identify the polymorphism. Patients were in stage II/III and received postoperative FOLFOX-4 chemotherapy. As a control group, an equal number of unrelated healthy subjects were enrolled in the study. The polymorphism was genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and results were compared with clinicopathological markers, early relapse and survival rates. During the 12 months of follow-up, local and distant recurrences were observed in 15 (30%) patients. No significant difference in the distribution of wild-type and polymorphic genotypes was observed between the patient and control groups and between the patients who experienced recurrence within 1 year and those who did not (all P>0.05). In conclusion, the G1249A polymorphism is not associated with CRC risk and early recurrence. However, significant correlation was observed between G1249A polymorphism and the overall survival and disease-free survival of the patients.

View Figures

View References

1	Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 25:2198–2204. 2007. View Article : Google Scholar
2	Chen LT and Whang-Peng J: Current status of clinical studies for colorectal cancer in Taiwan. Clin Colorectal Cancer. 4:196–203. 2004. View Article : Google Scholar : PubMed/NCBI
3	de Gramont AD, Tournigand C, André T, Larsen AK and Louvet C: Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol. 34(Suppl 1): S37–S40. 2007.
4	Schippinger W, Samonigg H, Schaberl-Moser R, et al: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 97:1021–1027. 2007. View Article : Google Scholar : PubMed/NCBI
5	Gonzalez-Haba E, García MI, Cortejoso L, et al: ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics. 11:1715–1723. 2010. View Article : Google Scholar : PubMed/NCBI
6	Casado E, De Castro J, Belda-Iniesta C, et al: Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clin Transl Oncol. 9:549–554. 2007. View Article : Google Scholar : PubMed/NCBI
7	Perez RP, Hamilton TC and Ozols RF: Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther. 48:19–27. 1990. View Article : Google Scholar : PubMed/NCBI
8	El-akawi Z, Abu-hadid M, Perez R, et al: Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett. 105:5–14. 1996. View Article : Google Scholar : PubMed/NCBI
9	Theile D, Grebhardt S, Haefeli WE and Weiss J: Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 78:1366–1373. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ballatori N, Hammond CL, Cunningham JB, Krance SM and Marchan R: Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol. 204:238–255. 2005. View Article : Google Scholar : PubMed/NCBI
11	Sun N, Sun X, Chen B, et al: MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 65:437–446. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nies AT and Keppler D: The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453:643–659. 2007. View Article : Google Scholar : PubMed/NCBI
13	Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, et al: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos. 33:896–904. 2005.PubMed/NCBI
14	Kroetz DL, Liu W, Nguyen TD, et al: 1249G>A polymorphism of ABCC2 (MRP2) is associated with altered gene expression in human liver. J Clin Oncol. 24(Suppl): 130722006.
15	Toh S, Wada M, Uchiumi T, et al: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet. 64:739–746. 1999. View Article : Google Scholar
16	Choi JH, Ahn BM, Yi J, et al: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 17:403–415. 2007. View Article : Google Scholar : PubMed/NCBI
17	Naesens M, Kuypers DR, Verbeke K and Vanrenterghem Y: Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 82:1074–1084. 2006. View Article : Google Scholar
18	Liedert B, Materna V, Schadendorf D, Thomale J and Lage H: Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol. 121:172–176. 2003. View Article : Google Scholar : PubMed/NCBI
19	Shen DW, Goldenberg S, Pastan I and Gottesman MM: Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol. 183:108–116. 2000.
20	Petrova DT, Nedeva P, Maslyankov S, et al: No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 134:317–322. 2008. View Article : Google Scholar
21	Nishioka C, Sakaeda T, Nakamura T, et al: MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci. 50:181–188. 2004.PubMed/NCBI
22	Xingsheng Y, Sekine M, Kurata H, et al: Single nucleotide polymorphisms in MRP2 gene and their significance on chemosensitivity of advanced ovarian cancer. J Pract Obstet Gynecol. 20:153–155. 2004.